Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02916524
Other study ID # 4492E
Secondary ID U01DC014922-01A1
Status Recruiting
Phase N/A
First received
Last updated
Start date April 20, 2018
Est. completion date July 31, 2023

Study information

Verified date April 2021
Source Boston University Charles River Campus
Contact Nishaat Mukadam, MA
Phone 617-353-2706
Email mukadamn@bu.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this investigation is to implement a computational model that can predict and optimize training and cross-language generalization patterns for bilingual persons with aphasia (BPA). The proposed work will determine the best possible treatment program for each individual patient even before they are rehabilitated. In addition, the computational model allows specification of variables such as age of acquisition, language exposure/proficiency, impairment and their systematic influence on a range of language rehabilitation outcomes.


Recruitment information / eligibility

Status Recruiting
Enrollment 48
Est. completion date July 31, 2023
Est. primary completion date July 31, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 85 Years
Eligibility Inclusion Criteria: - Any number of years of education - Bilingual: speaking both Spanish and English (or Chinese and English) with any degree of language proficiency prior to stroke - Aphasia secondary to a left-hemisphere stroke (diagnosed by a neurologist on the basis of clinical CT/MRI imaging or medical reports) - Aphasia resulting from stroke or dementia - Naming deficits must be present with concurrent lexical/semantic impairment - Visual and auditory acuity sufficient for all assessment and treatment procedures - Ability to understand study and follow study procedures for the entire length of the study Exclusion Criteria: - Premorbid history of speech/language disorder - Proficient in more than just Spanish and English (or Chinese and English) - Overt, behaviorally noticeable, attentional limitations that interfere with completing the experimental tasks - Active medical disease that may compromise participation (e.g., cancer undergoing acute treatment, unstable diabetes, renal or hepatic insufficiency, fluctuating systemic immunological disease such as systemic lupus erythematosis, etc.) - Currently taking medications that are known to exert significant effects on cognitive processes, such as neuroleptics, steroids, anticholinesterase inhibitors, etc. - Current drug or alcohol use or dependence that would interfere with adherence to study requirements, in the opinion of the principal investigator - Inability or unwillingness of individual to give written informed consent - Diagnosed with mental illness other than active depression - Neurological condition other than that which resulted in aphasia

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Semantic Feature Analysis (SFA)
SFA training entails having the speech-language pathologist (SLP) guide the participant through generation of pertinent semantic features for pictured treatment items (e.g., category membership, physical description, location of item in context, action associated with item). Treatment is applied to a set of items in the context of single-subject, multiple baseline designs so that replication of treatment effects could be evaluated within and across participants. Treatment will be administered two times per week until prescribed accuracy levels were met during treatment probes or a maximum number of treatment sessions was completed.

Locations

Country Name City State
United States Austin Speech Labs Austin Texas
United States Boston University Sargent College Boston Massachusetts
United States San Francisco State University San Francisco California

Sponsors (2)

Lead Sponsor Collaborator
Boston University Charles River Campus National Institute on Deafness and Other Communication Disorders (NIDCD)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Word Retrieval Accuracy in both languages Accuracy of naming of pictured treated and untreated items in both languages will be assessed in probes conducted separate from treatment. Probes were conducted repeatedly throughout the study, from baseline (prior to treatment) to the end of treatment. All naming responses were scored using as correct or incorrect. A percentage accuracy was calculated for each set of items for every probe session. Baseline probe scores were compared to end of treatment probe scores to obtain individual effect sizes for each sets of items for each participant (i.e., several effect sizes were calculated for each participant). Through study completion, an average of 10 weeks
Secondary Psycholinguistic assessments of language processing in aphasia (PALPA) in both languages Reading single words and understanding spoken words Week 1 and up to 10 weeks
Secondary Boston Naming Test (BNT) in both languages Naming pictured items Week 1 and up to 10 weeks
Secondary Bilingual Aphasia Test (BAT) B and C in both languages Assesses each of the languages of a bilingual or multilingual individual with aphasia Week 1 and up to 10 weeks
Secondary Western Aphasia Battery (WAB) in both languages Assesses the levels of impairment of aphasia Week 1 and up to 10 weeks
Secondary Cognitive Linguistic Quick Test (CLQT) in both languages Assesses the contribution of cognitive deficits to language dysfunction Week 1 and up to 10 weeks
Secondary Verbal fluency task (COWAT) in both languages Assesses general fluency Week 1 and up to 10 weeks
Secondary Category fluency task in both languages Assesses category fluency Week 1 and up to 10 weeks
Secondary Communication Effectiveness Index (CETI) for both languages Determines communication effectiveness by proxy Week 1 and up to 10 weeks
Secondary Pyramids and Palm Trees Test (PAPT) 3 pictures version Assesses semantic processing ability Week 1 and up to 10 weeks
Secondary Aphasia Bank Assesses discourse Week 1 and up to 10 weeks
See also
  Status Clinical Trial Phase
Completed NCT03622411 - Tablet-based Aphasia Therapy in the Chronic Phase N/A
Recruiting NCT03605381 - MORbidity PRevalence Estimate In StrokE
Recruiting NCT03929432 - Treatment Outcomes With tDCS in Post-Stroke Aphasia N/A
Completed NCT03662295 - Stroke-like Migraine Attacks After Radiation Treatment (SMART) Syndrome Language Intervention
Completed NCT03679637 - Tablet-based Aphasia Therapy in the Acute Phase After Stroke N/A
Completed NCT03228264 - A Trial Investigating Telerehabilitation as an add-on to Face-to-face Speech and Language Therapy in Post-stroke Aphasia. N/A
Completed NCT03550092 - Analysis of Brain Activity to Uncover Brain-behavior Relationships Related to Therapy Outcomes in Aphasia N/A
Suspended NCT04290988 - Circuitry Assessment and Reinforcement Training Effects on Recovery N/A
Recruiting NCT05969548 - pBFS-guided cTBS at Different Doses for Aphasia After Stroke N/A
Recruiting NCT04138940 - Modulating Intensity and Dosage of Aphasia Scripts N/A
Terminated NCT02249819 - Evaluating Anodal tDCS Preceding Aphasia Therapy Phase 1/Phase 2
Completed NCT01654029 - Patient Centred Communication Intervention N/A
Completed NCT00843427 - fMRI of Language Recovery Following Stroke in Adults N/A
Active, not recruiting NCT00227461 - Levetiracetam (Keppra) to Improve Chronic Aphasia in Post-stroke Patients. Phase 1
Completed NCT03773419 - Improving Electronic Written Communication in Aphasia N/A
Not yet recruiting NCT04142866 - Transcranial Direct Current Stimulation (tDCS) With Verb Network Strengthening Treatment (VNeST) in Chronic Aphasia N/A
Suspended NCT04048668 - tDCS to Treat Subacute Aphasia N/A
Recruiting NCT04081207 - Using Augmentative & Alternative Communication to Promote Language Recovery for People With Post-Stroke Aphasia N/A
Completed NCT02226796 - Transcranial Direct Stimulation (tDCS) and Behavioral Intervention in Aphasia N/A
Completed NCT01163461 - Phonomotor Treatment of Word Retrieval Deficits in Individuals With Aphasia N/A